ERBB2 and breast cancer: In conclusion, this study proposes that the yield of sentinel node biopsy and further axillary clearance in patients with screen-detected early breast cancer is very low, and omission of sentinel node biopsy could be considered in low-risk T1, postmenopausal, small tumors, which are hormone positive, HER2-negative, provided patients are compliant with the adjuvant treatment of radiotherapy and/or endocrine treatment. However, close follow-up will be required for disease-free survival, overall survival, and locoregional recurrence in this cohort.